Crizotinib: New Standard for ALK+ Myofibroblastic Tumor

Share this post

With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor — a very rare type of soft tissue sarcoma — crizotinib should be the standard of care, say experts.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply